0001642159 false 0001642159 2021-10-20 2021-10-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares














Date of report (Date of earliest event reported): October 20, 2021


(Exact Name of Registrant as Specified in Its Charter)


Delaware   333-204486   47-2573116

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


2468 Historic Decatur Road,    

Suite 140

San Diego, California

(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code: 619.368.2000


Prior address and phone number:


8880 Rio San Diego Drive    

Suite 800

San Diego, CA.

(Address of principal executive offices)   (Zip Code)


(213) 457-3772


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol   Name of each exchange on which registered
None   None   None


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







As used herein, the terms, “we,” “us,” “our,” and the “Company” refers to Sigyn Therapeutics, Inc., a Delaware corporation and its subsidiaries, unless otherwise stated.




This Form 8-K and other reports filed by Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) from time to time with the Securities and Exchange Commission (collectively, the “Filings”) contain or may contain forward looking statements and information that are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by the Company’s management. When used in the filings the words “anticipate”, “believe”, “estimate”, “expect”, “future”, “intend”, “plan” or the negative of these terms and similar expressions as they relate to the Company or Company’s management identify forward looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Company’s industry, the Company’s operations and results of operations and any businesses that may be acquired by the Company. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.


Although the Company’s management believes that the expectations reflected in the forward looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results. The following discussion should be read in conjunction with the Company’s pro forma financial statements and the related notes filed with this Form 8-K.


Item 1.01 Entry Into a Material Definitive Agreement.


On October 20, 2021, Sigyn Therapeutics, Inc. (the “Company”) consummated, with accredited investors, the sale of 1, shares of Company common stock and warrants to purchase an aggregate of 320,000 shares of the Company’s common stock and warrants for gross proceeds totaling $400,000. The purchase price per share of common stock and warrant was $1.25. Each warrant has a term of five years from the date of issuance and provides for the holder to purchase one share of the Company’s common stock at an exercise price of $1.25 per share. The sale of the shares and warrants is exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended.


Item 3.02 Unregistered Sale of Securities.


See Item 1.01.


Item 9.01. Financial Statements and Exhibits.


99.1   Form of Securities Purchase Agreement and Form of Warrant, dated October 20, 2021
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)







Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: October 25, 2021 By: /s/ James A. Joyce
    James A. Joyce, Chairman and CEO



Sigyn Therapeutics (QB) (USOTC:SIGY)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Sigyn Therapeutics (QB) Charts.
Sigyn Therapeutics (QB) (USOTC:SIGY)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Sigyn Therapeutics (QB) Charts.